Global Alopecia Areata Market Growth 2024, Forecast To 2033
8 Mar, 2024
Alopecia areata market rose from $3.31 billion in 2023 to $3.55 billion in 2024, with a 7.4% CAGR driven by limited treatment options. Expected growth to $4.73 billion in 2028 (CAGR: 7.4%) is expected. Trends encompass biologic therapies development and telemedicine in dermatology.
Global Alopecia Areata Market Key Driver
The alopecia areata market is expanding with the growing prevalence of hair loss, affecting 21 million women and 35 million men globally in 2022. Corticosteroids are commonly used in alopecia areata treatment to inhibit the immune system and promote hair regrowth, driving the demand for therapies to address hair loss.
Get A Free Sample Of The Global Alopecia Areata Market ReportGlobal Alopecia Areata Market Segments
The alopecia areata market covered in this report is segmented –
1) Type:Patchy Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Diffuse Alopecia Areata, Ophiasis Alopecia, Other Types
2) Treatment:Medical Treatments, Natural Treatment, Other Treatments
3) Diagnosis:Trichoscopy, Skin Biopsy, Other Diagnoses
4) Route Of Administration:Oral, Topical, Parenteral, Other Routes Of Administration
5) End-Users:Hospitals, Specialty Clinics, Homecare, Other End-Users
By Geography: The countries covered in the alopecia areata market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the alopecia areata market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alopecia areata market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Alopecia Areata Industry Players
Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; Sanofi S.A.; GlaxoSmithKline plc.; Eli Lilly and Co Ltd.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Perrigo Company plc; Bausch Health Companies Inc.; Incyte Corporation; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Taisho Pharmaceutical Holdings Co. Ltd.; Lupin Ltd.; Glenmark Pharmaceuticals Ltd.; Almirall S.A.; Torrent Pharmaceuticals Ltd.; Ranbaxy Laboratories Limited; Taro Pharmaceutical Industries Ltd.; G&W Laboratories Inc.; Vanda Pharmaceuticals Inc.; Aclaris Therapeutics Inc.; BioSplice Therapeutics Inc.; XBiotech Inc.; PureTech Health plc; HCell Inc.; Histogen Inc.
Get The Full Global Alopecia Areata Market Report
Alopecia Areata Market Overview
Alopecia areata, also known as spot baldness, refers to an autoimmune disorder where the immune system targets hair follicles, resulting in hair loss and patchy bald spots on the scalp, each about the size of a coin. It is a non-scarring condition that can affect individuals of all ages and characterized by the sudden loss of hair in small, soft, hairless patches.